Healthcare Unfiltered Express

Episode 57: The KOMET-007 Trial

19 min · I går
episode Episode 57: The KOMET-007 Trial cover

Beskrivelse

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.  A must listen - please share subscribe, and join the conversation.

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af Healthcare Unfiltered Express-fællesskabet!

Kom i gang

1 måned kun 9 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

57 episoder